Callio Therapeutics

Callio Therapeutics specializes in the development of advanced antibody-drug conjugates (ADCs) for cancer treatment. Their focus lies in creating multi-payload ADCs, which allow for the targeted delivery of drug combinations directly to tumor cells. This innovative approach aims to maximize therapeutic benefits and improve patient outcomes.

Piers Ingram Ph.D

Co-Founder, CEO and Board Member

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.